▲ NIFTY 50 top gainers HDFCLIFE₹557.00▲ 5.05% TMPV₹314.50▲ 4.49% SBILIFE₹1,766.90▲ 4.06% DRREDDY₹1,175.00▲ 3.07% BEL₹395.45▲ 2.51% INDIGO₹4,845.00▲ 2.36% TATASTEEL₹187.29▲ 2.34% JIOFIN₹229.30▲ 1.98% ETERNAL₹322.35▲ 1.69% SHRIRAMFIN₹995.00▲ 1.63% ▼ NIFTY 50 top losers ONGC₹232.43▼ 1.85% TITAN₹4,841.00▼ 1.38% HDFCBANK₹713.00▼ 1.18% COALINDIA₹418.00▼ 1.01% HINDUNILVR₹1,942.20▼ 1.01% NESTLEIND₹1,370.60▼ 1.00% ICICIBANK₹1,347.60▼ 0.82% BAJAJ-AUTO₹11,500.00▼ 0.80% GRASIM₹3,173.10▼ 0.44% WIPRO₹166.40▼ 0.29% NSE most active PNB₹116.47▼ 0.28% ITC₹266.20▲ 0.78% KOTAKBANK₹416.50▲ 0.36% CANBK₹123.90▲ 0.57%

NSE AJANTPHARM · BSE 532331 · Biotechnology & Drugs · NIFTY 500

Ajanta Pharma Share Price

Market closed · updated 25 Sep, 2:43 PM IST
₹3,549.20 ▼ −₹13.90 · 0.39% NSE · as of 24 Sep 2026, 9:58 AM · BSE ₹3,551.55
Today's range
₹3,519.55Low₹3,590.00High
52-week range
₹2,335.00Low · 30 Sep 2025₹3,796.95High · 18 Aug 2026

Ajanta Pharma Overview

Where the price stands, how it has moved and how it sits against its averages.

Ajanta Pharma shares last traded at ₹3,549.20 on the NSE, down 0.39% on the day. That is 6.5% below the 52-week high of ₹3,796.95 and 52.0% above the 52-week low of ₹2,335.00. The stock trades at 37.68× earnings, above the sector average of 36.50. Its market value is ₹44,377 Cr.

Price returns

1 Day▼ −0.39%
5 Days▲ +1.69%
This month▼ −0.94%
3 Months▲ +9.60%
6 Months▲ +23.90%
This year▲ +28.86%
1 Year▲ +40.21%

Against the market: 1 Month ▲ +4.01% · 3 Months ▲ +12.76% · 6 Months ▲ +24.63% · This year ▲ +46.76% · 1 Year ▲ +53.83%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 6 of 6

  1. Today's price₹3,549.20
  2. 10-day average₹3,531.19 ▲ price 0.5% above
  3. 20-day average₹3,530.36 ▲ price 0.5% above
  4. 5-day average₹3,526.88 ▲ price 0.6% above
  5. 50-day average₹3,519.20 ▲ price 0.9% above
  6. 100-day average₹3,326.10 ▲ price 6.7% above
  7. 300-day average₹3,061.50 ▲ price 15.9% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Ajanta Pharma Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
5,453
Net profit₹ crore · losses below zero
1,056

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹5,453 Cr ▲ +17.3% ₹1,056 Cr 19.4% ₹84.51 ₹28.00
FY 2025 ₹4,648 Cr ▲ +10.4% ₹920 Cr 19.8% ₹73.53 ₹28.00
FY 2024 ₹4,209 Cr ▲ +12.5% ₹816 Cr 19.4% ₹64.77 ₹10.00
FY 2023 ₹3,743 Cr ▲ +12.0% ₹588 Cr 15.7% ₹45.89 ₹7.00
FY 2022 ₹3,341 Cr ▲ +15.6% ₹713 Cr 21.3% ₹54.96 ₹6.33
FY 2021 ₹2,890 Cr ▲ +11.7% ₹654 Cr 22.6% ₹50.06 ₹6.33
FY 2020 ₹2,588 Cr — ₹468 Cr 18.1% ₹35.73 ₹8.67

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
26%
74%
  • Total assets₹6,155 Cr
  • Total liabilities₹1,628 Cr
  • Shareholders' equity₹4,527 Cr
  • Total debt₹260 Cr
  • Cash & investments₹663 Cr
  • Current ratio2.64×
  • Revenue growth, 5 yr13.54% a year
  • EPS growth, 5 yr11.04% a year
  • Operating margin (TTM)23.58%
  • Net margin (TTM)19.65%

Cash flow — FY26

Operating activities
▲ ₹529 Cr
Investing activities
▼ −₹429 Cr
Financing activities
▼ −₹168 Cr
Free cash flow
▲ ₹164 Cr
Net change in cash
▼ −₹68 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue2,587.872,889.693,340.993,742.644,208.714,648.105,452.86
Cost of revenue690.23682.39886.721,116.731,115.321,127.151,254.47
Gross profit1,897.642,207.302,454.272,625.913,093.393,520.954,198.39
Operating expenses2,004.082,005.012,533.123,062.043,156.083,519.644,126.26
Operating income583.79884.68807.87680.601,052.631,128.461,326.60
Depreciation95.23115.60124.82130.31135.40144.11173.14
Profit before tax663.97900.18909.48745.251,113.931,189.161,377.65
Tax196.27246.31196.79157.27297.76268.77321.65
Net profit467.70653.87712.69587.98816.17920.391,056.00
EPS (₹)35.7350.0654.9645.8964.7773.5384.51
Dividend per share (₹)8.676.336.337.0010.0028.0028.00

What Analysts Say

15 analysts

Recommendations from 15 analysts who cover Ajanta Pharma.

Buy average rating 2.07 on a 1–5 scale

▲ 10 bullish (66.7%) · 3 hold (20.0%) · ▼ 2 bearish (13.3%)

Votes

Strong Buy
6 (40%)
Buy
4 (27%)
Hold
3 (20%)
Sell
2 (13%)
Strong Sell
0 (0%)

How the votes changed

Rating3M ago2M ago1M ago1W agoNow3-month change
Strong Buy77666 ▼ −1
Buy66444 ▼ −2
Hold11333 ▲ +2
Sell11222 ▲ +1
Strong Sell00000 —

Analyst ratings are opinions, not a guarantee of returns.

Ajanta Pharma vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yieldRating
Ajanta Pharma ₹3,549.20 ▼ −0.39% ₹44,377 Cr 37.68 9.85 23.03% 19.65% 0.78% This stock
Sun Pharmaceutical Industries ₹1,853.00 ▼ −0.64% ₹4,44,586 Cr 38.40 5.55 14.22% 19.12% 0.83% Moderately Bearish
Divi's Laboratories ₹9,613.00 ▲ +0.17% ₹2,55,195 Cr 73.32 11.48 16.87% 24.32% 0.41% Bullish
Torrent Pharmaceuticals ₹4,935.00 ▼ −0.90% ₹1,87,705 Cr 72.73 19.22 23.00% 15.29% 0.80% Bullish
Cipla ₹1,404.00 ▲ +1.74% ₹1,13,423 Cr 27.57 3.33 14.47% 13.74% 0.92% Neutral
Zydus Lifesciences ₹1,180.00 ▲ +0.90% ₹1,17,705 Cr 21.19 4.24 17.90% 18.51% 0.09% Bullish

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Ajanta Pharma shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
63.5%
18.1%
10.7%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter66.25%66.25%66.25%63.48% ▼ −2.77 pts
FII8.53%7.97%8.26%7.68% ▼ −0.58 pts
MF14.67%15.49%15.22%18.10% ▲ +2.88 pts
Other10.55%10.29%10.27%10.74% ▲ +0.47 pts

Ajanta Pharma Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Ajanta PharmaBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share
37.68
▲ 3% above the sector average of 36.50
P/E, 12-month rangeLow 21.79 · high 46.03
66%
Today's P/E sits 66% of the way from its low to its high
P/BPrice ÷ book value per share
9.85
P/SPrice ÷ sales per share
7.72
P/CFPrice ÷ cash flow per share
34.00
PEGP/E ÷ earnings growth (≈1 is fair)
1.74

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
78.61%
▲ above its 5-yr average of 74.29%
Operating marginKept after running costs
23.58%
▲ above its 5-yr average of 23.35%
Pre-tax marginKept before tax
25.85%
▲ above its 5-yr average of 24.94%
Net marginKept as profit
19.65%
▲ above its 5-yr average of 19.13%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
25.39%
▲ above its 5-yr average of 23.03%
Return on assetsProfit on everything it owns
18.91%
▲ above its 5-yr average of 17.53%
Return on investmentProfit on long-term capital
24.12%
▲ above its 5-yr average of 21.95%

Growth Is the business getting bigger?

Revenue — last 12 months
+20.2%
▲ growing
Revenue — 3 yr, a year
+13.4%
▲ growing
Revenue — 5 yr, a year
+13.5%
▲ growing
EPS — last 12 months
+22.2%
▲ growing
EPS — 3 yr, a year
+22.6%
▲ growing
EPS — 5 yr, a year
+11.0%
▲ growing
Dividend — 3 yr, a year
+58.7%
▲ growing (off the scale)
Book value — 5 yr, a year
+9.4%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.06×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
2.64×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
1.93×
✓ Comfortable
Payout ratioShare of profit paid as dividend
33.13%
✓ Balanced

Per share What each share stands for

EPS (TTM)
₹90.83
Book value
₹362.46
Cash flow
₹104.95
Dividend
₹28.00
Revenue
₹462.31

The share price is 9.79× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 108 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year42.22
Current Dividend Yield - Common Stock Primary Issue, LTM0.78
Price to Book - most recent fiscal year9.85
P/E Basic excluding extraordinary items - TTM37.68
P/E including extraordinary items - TTM39.28
P/E excluding extraordinary items low, trailing 12 months21.79
Price to Tangible Book - most fiscal year9.94
Dividend Yield - 5 Year Average0.79
Price to sales - most recent fiscal year8.18
Dividend Yield - indicated annual dividend divided by closing price1.49
Price to Cash Flow per share - trailing 12 month34.00
Peg Ratio1.74
P/E Normalized, most recent fiscal year42.16
P/E excluding extraordinary items high, trailing 12 months46.03
P/E excluding extraordinary items, most recent fiscal year quarter39.28
Price to sales - trailing 12 month7.72
Net Debt, LFY−4,032.50

Per share

Dividend Per Share - 5 year average15.87
Cash Flow per share - trailing 12 month104.95
Cash Flow per share - most recent fiscal year98.37
EPS including extraordinary items - trailing 12 month90.83
EPS including extraordinary items - most recent fiscal year84.51
EBITD per share - trailing 12 month123.15
Revenue/share - trailing 12 month462.31
EPS excluding extraordinary items - trailing 12 month90.83
EPS Basic excluding extraordinary items - most recent fiscal year84.53
EPS Basic excluding extraordinary items - trailing 12 month90.84
Book value per share - most recent fiscal year362.35
Dividend per share - most recent fiscal year28.00
Revenue/share - most recent fiscal year436.40
EPS Normalized - most recent fiscal year84.63
Book value (tangible) per share - most recent fiscal year359.03
Dividends per share - trailing 12 month28.00
EPS excluding extraordinary items - most recent fiscal year84.51
Cash per share - most recent fiscal year53.10

Margins

Operating margin - trailing 12 month23.58
Gross Margin - 5 year average74.29
Operating margin - 1st historical fiscal year24.33
Operating Margin - 5 year average23.35
Net Profit Margin % - 1st historical fiscal year19.37
Gross Margin - 1st historical fiscal year76.99
Net Profit Margin % - trailing 12 month19.65
Net Profit Margin - 5 year average19.13
Pretax Margin - 5 year average24.94
Pretax margin - 1st historical fiscal year25.26
Pretax margin - trailing 12 month25.85
Free Operating Cash Flow/Revenue, 5 Year Average5.39
Gross Margin - trailing 12 month78.61

Growth

EPS Change %, TTM over TTM22.22
Revenue growth rate, 5 year13.54
EPS growth rate, 5 year11.04
Revenue Change % - most recent quarter 1 year ago24.82
Growth rate% - dividend, 3 year58.74
Growth rate% - EPS, 3 year22.57
Revenue/share (5 yr growth)14.55
Tangible Book Value, Total Equity, 5 Year CAGR8.49
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR9.10
Capital Spending growth rate, 5 year16.30
Revenue Change %, TTM over TTM20.19
Growth rate% - Revenue, 3 year13.37
Book value per share growth rate, 5 year9.44
EPS Change % - most recent quarter 1 year ago30.93
Net Profit Margin growth rate, 5 year−3.07
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR8.26
Total Debt, 5 Year CAGR52.68

Financial strength

Free Cash Flow - most recent fiscal year−1,856.90
LT debt/equity - most recent fiscal year0.01
Quick ratio - most recent fiscal year1.93
Payout ratio - trailing 12 month30.82
Current ratio - most recent fiscal year2.64
Current EV/Free Cash Flow, LFY85.92
Total debt/total equity - most recent fiscal year0.06
Payout ratio - most recent fiscal year33.13

Returns & efficiency

Return on average equity - 5 year average23.03
Net Income/employee - trailing 12 month10,89,032.00
Revenue/employee - most recent fiscal year54,39,533.00
Return on investment - most recent fiscal year24.12
Return on average assets - most recent fiscal year18.91
Receivables turnover - most recent fiscal year3.58
Inventory turnover - most recent fiscal year1.29
Revenue/employee - trailing 12 month55,42,818.00
Return on average assets - 5 year average17.53
Net Income/employee - most recent fiscal year10,53,419.00
Asset turnover - most recent fiscal year0.98
Return on average equity - most recent fiscal year25.39
Return on investment - 5 year average21.95

Price & volume

Market Cap44,377.31
52 week Low Date30 Sep 2025
Price - 1 Day % Change1.39
Relative (S&P500) price percent change - 13 week12.76
Avg trading volume last 10 days0.09
Price - 13 week price percent change9.60
Price - 52 week price percent change40.21
Avg Trading Volume Last 3 months2.24
Price - 5 Day % Change1.69
Price % Change Month To Date−0.94
Relative (S&P500) price percent change - 04 week4.01
52 week High Date18 Aug 2026
Price - 26 week price percent change23.90
PDATE23 Sep 2026
Price - YTD price percent change28.86
Relative (S&P500) price percent change - 52 week53.83
NPRICE3,568.10
Relative (S&P500) price percent change - 26 week24.63
52 week Low2,329.90
52 week High3,796.00
Beta0.74
Relative (S&P500) price percent change - Year to Date46.76

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹28.00
₹28.00
  • Dividend yield0.78%
  • Payout ratio33.13%
  • 5-year average dividend₹15.87 a share
  • Latest dividend₹32.00 per share · 5 Aug 2026

Corporate calendar

  • Dividend₹32.00 per share · 1,600% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • MeetingAnnual General Meeting
  • BoardAudited Results
  • BoardQuarterly Results
  • Dividend₹28.00 per share · 1,400% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • BoardQuarterly Results & Others
Show 15 older events
  • MeetingAnnual General Meeting
  • BoardAudited Results & A.G.M.
  • BoardQuarterly Results
  • Dividend₹28.00 per share · 1,400% · Interim dividend
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • MeetingOthers
  • Dividend₹26.00 per share · 1,300% · Interim dividend
  • Dividend₹15.00 per share · 750% · Special special dividend
  • Dividend₹10.00 per share · 500% · Interim dividend
  • MeetingAnnual General Meeting
  • MeetingPostal Ballot
  • Dividend₹7.00 per share · 350% · Interim dividend
  • BonusBonus issue in the ratio of 1:2 of Rs. 2/-.
  • Dividend₹9.50 per share · 475% · Interim dividend

About Ajanta Pharma

Biotechnology & Drugs

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.

Key people

  • Madhusudan Bhagwandas AgrawalExecutive Vice Chairman of the Board
  • Arvind K. AgrawalChief Financial Officer
  • Gaurang C. ShahVice President - Legal, Company Secretary
  • Rajesh Mannalal AgrawalJoint Managing Director, Executive Director
  • Yogesh Mannalal AgrawalManaging Director, Executive Director

Company facts

  • NSE symbolAJANTPHARM
  • BSE code532331
  • ISININE031B01049
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹44,377 Cr
  • Revenue (FY26)₹5,453 Cr
  • Net profit (FY26)₹1,056 Cr

In the News

Recent headlines about Ajanta Pharma — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Ajanta Pharma (NSE: AJANTPHARM) last traded at ₹3,549.20 on the NSE, down 0.39% (₹13.90) on the day, as of 24 Sep 2026, 9:58 AM. On the BSE it was ₹3,551.55. The day's range was ₹3,519.55 – ₹3,590.00.

Ajanta Pharma's 52-week high is ₹3,796.95 (18 Aug 2026) and its 52-week low is ₹2,335.00 (30 Sep 2025). At ₹3,549.20 the share is 6.5% below its high and 52.0% above its low.

Ajanta Pharma's market capitalisation is ₹44,377 Cr (₹44,377 Cr). It is part of the NIFTY 500 index.

Ajanta Pharma's P/E ratio (trailing 12 months) is 37.68. The sector average is 36.50, so investors pay 3% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹90.83.

Ajanta Pharma shares are up 40.21% over the last year, up 28.86% so far this year, up 23.90% over 6 months, up 9.60% over 3 months. Over the last year the stock did 53.83% better than the market.

In FY26 (year to Mar 2026), Ajanta Pharma reported revenue of ₹5,453 Cr (up 17.31% on the year before) and a net profit of ₹1,056 Cr. Earnings per share were ₹84.51.

Yes. Ajanta Pharma's latest dividend is ₹32.00 per share (1,600%, interim dividend), with an ex-date of 5 Aug 2026. The dividend yield is 0.78%. It has paid 8 dividends in the records shown on this page.

Of 15 analysts covering Ajanta Pharma, 10 are bullish (6 strong buy, 4 buy), 3 say hold and 2 are bearish. The consensus is Buy (average rating 2.07 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 63.48%, FII 7.68%, MF 18.10%, Other 10.74%. Promoter holding fell by 2.77 percentage points from Mar 2026.

Ajanta Pharma's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.